ramucirumab in squamous non-small cell lung cancer
Published 8 years ago • 150 plays • Length 6:44Download video MP4
Download video MP3
Similar videos
-
3:25
use of ramucirumab for patients with squamous or nonsquamous lung cancer
-
6:02
ramucirumab in nsclc
-
4:16
ramucirumab data for lung cancer
-
6:11
patient selection for ramucirumab in nsclc
-
1:46
dr. martin reck on docetaxel/ramucirumab in nsclc
-
6:18
treating nsclc with ramucirumab: the revel trial
-
2:48
ramucirumab in relapsed/refractory nsclc
-
15:25
targeted therapies: the future of non-small cell lung cancer (nsclc) treatment?
-
4:08
ramucirumab approval expanded, breakthrough designation for crizotinib, and more
-
4:30
rationale for ramucirumab in nsclc
-
7:24
optimal sequencing in squamous non-small cell lung cancer
-
6:45
lung adenocarcinoma: patient selection with ramucirumab vs nintedanib
-
6:42
ramucirumab after progression in advanced hcc
-
5:18
update on treatment of metastatic non-small cell lung cancer
-
4:42
ramucirumab data for colorectal cancer
-
6:41
relay: erlotinib with ramucirumab for egfr nsclc
-
7:28
does cyramza (ramucirumab) make difference for second line treatment?
-
9:22
determining the optimal treatment in advanced non-squamous non-small cell lung cancer
-
5:18
ramucirumab docetaxel as second-line therapy in non-driver nsclc